Skip main navigation (Press Enter).
Log in
Toggle navigation
Log in
Education & Science
40th Annual Meeting & Pre-Conference Programs
Past and Future Annual Meetings
Advances in Cancer Immunotherapy
SITC Biotech Initiative
SITC Biotech Strategic Meeting at NYSE
SITC Biotech Virtual Programs
SITC Neoadjuvant Initiatives
Cancer Immunotherapy Winter School
Spring Scientific
Collaborative Education Programs
Patient & Survivor Resources
ConnectED
Webinars and Virtual Workshops
Upcoming Events
Summits and Initiatives
Career Development
Certificate in Cancer Immunotherapy
Fellowships
Women in Cancer Immunotherapy Network
Sparkathon
SITC Clinical Immuno-Oncology Network (SCION) Workshop
Clinical Trials Training and Resources
Early Career Scientist (ECS) Committee
Path to SITC Leadership
Publications & Guidelines
Journal for ImmunoTherapy of Cancer
SITC Clinical Practice Guidelines
SITC Immunotherapy Books
SITC Scientific Publications News
About
Mission & Vision
Strategic Plan
Elevating a Rich Oncology Community - SITC’s DEI Strategic Plan
Board of Directors
Committees, Task Forces, & Communities
Awards and Recognition
Academy of Immuno-Oncology
SITC Policies
Contact SITC
SITC News
Get Involved
Join SITC
Connect-a-Colleague
Corporate Membership
International Membership
Member Directory
Support SITC
Policy & Advocacy
2025 SITC Election
Committees, Task Forces, & Communities
Career Connections
Volunteer with SITC
Enduring Materials
Events
For Patients
Join
Renew
Donate
My Libraries
TCR Based Therapeutics: A Deep Dive in Targets for Cancer IO
×
When:
Dec 7, 2022 from 14:00 to 16:00 (CT)
This webinar, the eighth of the 2022 Targets for Cancer IO: A Deep Dive Series, will discuss the research and clinical findings behind therapies involving T cell receptors. Basic, clinical and translational researchers in academia and industry and members of the investment community are the target audience of this series.
Moderators
:
Harlan Robins, PhD –
Adaptive Biotechnologies Corporation
Faculty
:
David Berman, MD, PhD -
Immunocore
Aude Chapuis, MD -
Fred Hutchinson Cancer Center
Ira Mellman, PhD
- Genentech
Learn more about the 2022 Targets for Cancer IO: A Deep Dive Series
here
!
Targets for Cancer IO: A Deep Dive Series
is supported, in part, by educational grants from Genmab, US, Inc. and Merck & Co., Inc.
(
as of 6/6/2022
).
#TargetsforCancerImmunotherapyADeepDiveSeminarSeries
#NoCEOffered
#Industry
#Researcher
#2022
Download to Your Calendar
Contact
education@sitcancer.org
Related Content
Targets for Cancer IO: A Deep Dive, TCR based Therapeutics
SITC Education
Added 12-12-2022
Library Entry
Targeted systemic delivery of innate immune activators: A Deep Dive in Targets for Cancer IO
Added 06-29-2022
Event
Enhanced CTLA-4 blockade: A Deep Dive in Targets for Cancer IO
Added 06-29-2022
Event
Recombinant Interleukin-18 Immunotherapy: A Deep Dive in Targets for Cancer IO
Added 06-27-2022
Event
NK Cell Engagers: A Deep Dive in Targets for Cancer IO
Added 06-29-2022
Event
Copyright 2025. All rights reserved.
Powered by Higher Logic